CABA-201

PreclinicalCell therapy

CCabaletta Bio

CABA-201 is one of 157 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

156

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Pemphigus VulgarisActive, not recruiting

Myasthenia GravisActive, not recruiting

Systemic SclerosisActive, not recruiting

Multiple SclerosisActive, not recruiting

Relapsing Multiple SclerosisWithdrawn

Systemic Lupus ErythematosusPhase 1/Phase 2

Active, not recruiting

Pemphigus VulgarisPhase 1/Phase 2

Active, not recruiting

Myasthenia GravisPhase 1/Phase 2

Active, not recruiting

Systemic SclerosisPhase 1/Phase 2

Active, not recruiting

Multiple SclerosisPhase 1/Phase 2

Active, not recruiting

Relapsing Multiple SclerosisPreclinical

Withdrawn

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Betaseron

Bayer

Preclinical

16 2

Kesimpta

Novartis

Preclinical

15 3

Tysabri

Biogen

Preclinical

14 4

Campath

GGenzyme, a Sanofi Company

Preclinical

12 5

Pred Forte

Myfortic

Novantrone

Circadin

NNeurim Pharmaceuticals Ltd.

Preclinical

3 9

Lunesta

Akero Therapeutics

Preclinical

1 10

XEOMIN

MMerz Pharmaceuticals GmbH

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1/2Recruiting

Pemphigus Vulgaris

NCT04422912

Q3 2029

Phase 1/2Recruiting

Systemic Sclerosis

NCT06328777

Phase 1/2Active, not recruiting

Myasthenia Gravis

NCT06359041

Q4 2029

Phase 1/2Recruiting

Systemic Lupus Erythematosus

NCT06121297

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Recruiting·CCabaletta Bio·Phase 1/2·NCT06121297·28 enrolled

Myasthenia Gravis1 trial

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Active, not recruiting·CCabaletta Bio·Phase 1/2·NCT06359041·12 enrolled

Systemic Sclerosis1 trial

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Recruiting·CCabaletta Bio·Phase 1/2·NCT06328777·12 enrolled

Pemphigus Vulgaris1 trial

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Recruiting·CCabaletta Bio·Phase 1/2·NCT04422912·40 enrolled

Relapsing Multiple Sclerosis1 trial

RESET-MS: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Multiple Sclerosis

Withdrawn·CCabaletta Bio·Preclinical·NCT07006805

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for CABA-201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CABA-201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CABA-201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cabaletta Bio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: CCabaletta Bio

CABA-201

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q3 2029

Q4 2029

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

Myasthenia Gravis1 trial

Systemic Sclerosis1 trial

Pemphigus Vulgaris1 trial

Relapsing Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News